Health World Mauritania: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health World Mauritania.

Press releases published on October 26, 2026

Oct. 26, 2026

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

Indeterminate GlobeNewswire

Oct. 26, 2026

VETmAb Biosciences Announces Positive Clinical Proof-of-Concept Results for Long-Acting Anti-IL-23 Antibody in Canine Chronic Inflammatory Enteropathy

Indeterminate GlobeNewswire

Oct. 26, 2026

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Indeterminate GlobeNewswire

Oct. 26, 2026

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

Indeterminate GlobeNewswire

Oct. 26, 2026

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Indeterminate GlobeNewswire

Oct. 26, 2026

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis

Indeterminate GlobeNewswire

Oct. 26, 2026

BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients

Indeterminate GlobeNewswire

Oct. 26, 2026

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

Indeterminate GlobeNewswire

Oct. 26, 2026

Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine

Indeterminate GlobeNewswire

Oct. 26, 2026

Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026

Indeterminate GlobeNewswire

Oct. 26, 2026

InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization

Indeterminate GlobeNewswire

Oct. 26, 2026

Newsweek Places KFSH in Top 4% of World's Smart Hospitals for Digital Maturity and AI

Indeterminate GlobeNewswire

Oct. 26, 2026

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Indeterminate GlobeNewswire

Oct. 26, 2026

BioNTech und DualityBio geben Topline-Ergebnisse der globalen klinischen Phase-3-Studie DYNASTY-Breast02 für Trastuzumab Pamirtecan bei metastasiertem HR+/HER2-low-Brustkrebs bekannt

Indeterminate GlobeNewswire

Oct. 26, 2026

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

Indeterminate GlobeNewswire

Oct. 26, 2026

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Indeterminate GlobeNewswire

Oct. 26, 2026

Phathom Pharmaceuticals Provides Update on FDA Litigation

Indeterminate GlobeNewswire

Oct. 26, 2026

Microbiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026

Indeterminate GlobeNewswire

Oct. 26, 2026

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

Indeterminate GlobeNewswire